BioWorld

Nov. 2, 2009

View Archived Issues

Novartis Passes on Idenix Lead HCV Antiviral Drug

Idenix Pharmaceuticals Inc. is looking to partner its early stage compound for hepatic C virus (HCV), now that Swiss drugmaker Novartis Pharma AG has taken a pass on it. (BioWorld Today) Read More

House Health Care Bill Could be Problematic for Drugmakers

Read More

Biotech Dollars Continue Flowing with Innovation Getting Its Share

Read More

Findings May Impact How the Other Half Lives with Hepatitis

Read More

HCV Vaccines, TLRs Advance Away from Protease Spotlight

Read More

Other News To Note

Read More

Clinic Roundup

Read More

Financings Roundup

Read More